Pleconaril is an antiviral drug from viral capsid inhibitor class, manufactured by Schering-Plough and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic patients who... It acts by inhibiting viral replication.
- Mechanism
- Curator reviewed
Pleconaril binds to a hydrophobic pocket in viral protein 1, the major protein which makes up the capsid (shell) of picornaviruses. This renders the viral capsid rigid and compressed and prevents the uncoating of its RNA. As a result, the virus is stopped from attaching to the host cell and causing infection.
- Primary indication
- Investigated for use/treatment in upper respiratory infection.Curator reviewed
- Formula / weight
- C18H18F3N3O3 · 381.349 g/mol (avg)
- Code names
- VP 63843 · WIN 63843
Resolves to
KQOXLKOJHVFTRN-UHFFFAOYSA-NSMILESCC1=NOC(CCCOC2=C(C)C=C(C=C2C)C2=NOC(=N2)C(F)(F)F)=C1What you can answer from here — as of February 21, 2021
Which drugs share a target with Pleconaril, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account